Teva Prepares To Fight Appeal After US Narcan Victory
Four Patents For Naloxone Spray Invalidated By District Court, But Appeal Looms
Teva has won a US district court victory invalidating four patents protecting the Narcan naloxone nasal spray. However, despite holding FDA approval for a generic, the Israeli firm believes the battle is far from over.
You may also be interested in...
Padagis has added fresh competition on Narcan in the US, with its nasal naloxone spray introduced to the market as part of a trio of launches that also includes adapalene gel and betamethasone ointment.
Shortly after agreeing to provide the state of Texas with its generic version of Emergent BioSolutions’ Narcan (naloxone) 4mg nasal spray, Teva has secured victory in patent-invalidity proceedings.
Teva has delivered the launch of the first generic rival to Narcan naloxone 4mg nasal spray in the US. Sandoz has immediately responded with the introduction of an authorized generic.